SciClone Pharmaceuticals, Inc. (SCLN) Updates 2011 Financials and Provides Initial Guidance for 2012
SciClone Pharmaceuticals, Inc. is a specialty pharmaceutical company with a substantial commercial business in China. Its product portfolio, of nearly 20 drugs sold in over 30 countries, includes therapies for oncology, infectious diseases, and cardiovascular, urological, respiratory, and central nervous system disorders. The company today announced its anticipated full-year 2011 revenues and cash position. For 2011, SciClone anticipates revenues of approximately $134 million, including revenues from Nova Med Pharmaceuticals which was acquired in April 2011. This figure is a 57% increase over the 2010 level. The cash position as of December 31, 2011 is expected to be $66 million versus…